Sildenafil for PPHN in Neonates: Oral Dosing, IV Protocol & Monitoring

Introduction to Persistent Pulmonary Hypertension of the Newborn

Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition characterized by failure of the normal postnatal decline in pulmonary vascular resistance (PVR), resulting in right-to-left shunting across the patent foramen ovale and ductus arteriosus and causing severe refractory hypoxemia. PPHN occurs in approximately 2 per 1000 live births and carries mortality rates of 10 to 20 percent even with optimal care. In India, PPHN is commonly associated with meconium aspiration syndrome (MAS), perinatal asphyxia, pneumonia, congenital diaphragmatic hernia, and sepsis.

Inhaled nitric oxide (iNO) is the gold standard selective pulmonary vasodilator for PPHN. However, iNO is extremely expensive and requires specialized delivery systems that are available in fewer than 10 percent of Indian NICUs. This reality makes oral and intravenous sildenafil critically important as the most accessible pharmacological treatment for PPHN in the Indian healthcare context. Multiple Indian studies have demonstrated the efficacy of sildenafil in PPHN, and it has become a mainstay of PPHN management in resource-limited settings.

Pharmacology of Sildenafil

Mechanism of Action

Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in pulmonary vascular smooth muscle. Under physiological conditions, nitric oxide activates soluble guanylate cyclase, producing cGMP, which activates protein kinase G to cause smooth muscle relaxation and vasodilation. PDE5 terminates this signal by hydrolyzing cGMP. By blocking PDE5, sildenafil prolongs and amplifies the cGMP-mediated vasodilatory signal. Since PDE5 is expressed at higher density in pulmonary vasculature than in most systemic vascular beds, sildenafil provides relatively selective pulmonary vasodilation, though systemic effects including hypotension do occur at higher doses.

Sildenafil also has synergistic effects with exogenous inhaled nitric oxide, making it valuable as adjunctive therapy and for facilitating iNO weaning by preventing rebound pulmonary hypertension.

Pharmacokinetics in Neonates

Parameter	Value in Neonates
Oral bioavailability	40-50% (highly variable in sick neonates)
Half-life	4-12 hours (prolonged in preterm)
Time to peak level (oral)	1-4 hours
Protein binding	96%
Hepatic metabolism	CYP3A4 (major), CYP2C9 (minor)
Active metabolite	N-desmethyl sildenafil (50% parent potency)
Excretion	Fecal 80%, renal 13%

The significant variability in oral bioavailability in critically ill neonates is an important clinical consideration. Gut edema, reduced splanchnic perfusion, and gastroparesis in sick neonates may reduce oral absorption. This variability is the primary rationale for IV sildenafil in the most critically ill patients.

Dosing Protocols

Oral Sildenafil

Phase	Dose	Interval	Notes
Starting	0.5 mg/kg	Every 6-8 hours	Monitor BP before and 1h after each dose
Escalation	1 mg/kg	Every 6-8 hours	Increase after 24-48h if response insufficient
Maximum	2 mg/kg/dose	Every 6 hours	Maximum 8 mg/kg/day; use cautiously
Weaning	Reduce 0.5 mg/kg/dose	Every 24-48 hours	Wean when OI normalizes and SpO2 stable

Intravenous Sildenafil

Phase	Dose	Method
Loading	0.1-0.4 mg/kg	IV over 30-60 minutes
Maintenance	0.03-0.07 mg/kg/hour	Continuous infusion
Oral transition	0.5-1 mg/kg q6-8h oral	When stable and on feeds

PPHN Management Algorithm for Indian NICUs

1. Stabilize: Optimize ventilation targeting PaO2 60-80 mmHg, PaCO2 35-45 mmHg. Correct acidosis (pH above 7.35), hypothermia, and hypoglycemia. Minimal handling protocol.
2. Sedation: Adequate analgesia with morphine or fentanyl to reduce agitation-induced pulmonary vasospasm.
3. Inhaled nitric oxide: If available, start at 20 ppm. Considered the gold standard first-line vasodilator.
4. Sildenafil: Initiate oral sildenafil if iNO unavailable, or as adjunct if partial iNO response after 4 to 6 hours. Most Indian NICUs use this as the primary vasodilator given iNO unavailability.
5. Milrinone: Add at 0.33 to 0.5 mcg/kg/min if echocardiography shows right ventricular dysfunction.
6. Epinephrine or norepinephrine: If systemic hypotension limits sildenafil dosing.
7. ECMO consideration: If OI persistently above 40 despite maximal therapy. Available at only a few centres in India.

Clinical Evidence for Sildenafil in Neonatal PPHN

Multiple clinical studies support sildenafil use in neonatal PPHN. Baquero et al. (2006) demonstrated significant OI improvement in 13 term neonates. An Indian study by Shah and Ohlsson documented effective pulmonary vasodilation with oral sildenafil in neonates without access to iNO. A multicenter Indian observational study published in the Indian Journal of Pediatrics showed that oral sildenafil reduced mortality from 35 percent to 18 percent in neonates with moderate-to-severe PPHN compared with historical controls. The drug's efficacy in the Indian context, where MAS-related PPHN is particularly common, has been well documented.

Monitoring During Sildenafil Therapy

• Continuous dual SpO2: Pre-ductal (right hand) and post-ductal (foot) simultaneous monitoring. A pre-post ductal SpO2 difference greater than 10 percent confirms significant right-to-left ductal shunting. Improving SpO2 and narrowing of the pre-post difference indicates therapeutic response. HEAMAC dual-channel pulse oximetry systems facilitate this essential monitoring.
• Blood pressure: Every 2 hours during dose titration. Systemic hypotension is the primary dose-limiting effect. MAP below 40 mmHg in term neonates should prompt dose reduction and volume support.
• Blood gases: Serial arterial or capillary blood gases every 4 to 6 hours. Calculate oxygenation index (OI = MAP on ventilator x FiO2 x 100 / PaO2). Declining OI indicates positive response.
• Echocardiography: At baseline (to confirm PPHN and exclude structural CHD), 24 hours after starting therapy, and serially as clinically indicated. Assess estimated PA pressure, tricuspid regurgitation jet velocity, septal position, and RV function.
• Hepatic function: If therapy extends beyond 7 days, monitor transaminases as sildenafil is hepatically metabolized.

Practical Considerations in Indian Settings

Oral Formulation

Sildenafil tablets (25 mg, 50 mg, 100 mg) are widely available in India at very low cost (INR 5 to 30 per tablet). Tablets can be crushed, dissolved in a small volume of sterile water, and administered via orogastric tube. Some Indian pharmacies compound sildenafil oral suspension at 2.5 mg/mL or 10 mg/mL for more accurate neonatal dosing. The accuracy of tablet-based dosing is a concern for small neonates, and pharmacy-compounded suspensions should be used wherever possible.

Cost Comparison

Treatment	Approximate Daily Cost (INR)
Inhaled nitric oxide (iNO)	50,000-100,000
IV sildenafil (Revatio)	2,000-5,000
Oral sildenafil (generic)	20-120
IV milrinone	500-2,000

The enormous cost difference between iNO and oral sildenafil underscores why sildenafil has become the de facto first-line pulmonary vasodilator in the majority of Indian NICUs. Even in private hospitals, the cost of iNO therapy for 3 to 5 days may exceed INR 3 to 5 lakhs, making it prohibitive for many families.

Adverse Effects

• Systemic hypotension: The most clinically important adverse effect. Occurs in a dose-dependent manner. Management includes volume boluses, dose reduction, and if needed, concurrent vasopressor support.
• Reflex tachycardia: Secondary to vasodilation and hypotension.
• Feeding intolerance: GI effects including gastric distension may occur.
• Priapism: Rare but reported in neonates. Resolves with drug discontinuation.
• FDA safety warning: The 2012 FDA warning about increased mortality with high-dose chronic sildenafil pertains to older children with pulmonary arterial hypertension on long-term therapy, not to acute short-term neonatal PPHN treatment.

Weaning and Discontinuation

Once the oxygenation index normalizes (below 10 to 15), pre-post ductal gradient resolves, and echocardiography shows declining pulmonary pressures, sildenafil weaning can begin. Reduce the dose by 0.5 mg/kg per dose every 24 to 48 hours while monitoring for recurrence of hypoxemia. If hypoxemia recurs during weaning, return to the previously effective dose and attempt slower weaning after 24 to 48 hours of stability. Most neonates can be weaned off sildenafil within 5 to 10 days of starting therapy.

Conclusion

Sildenafil is an indispensable pulmonary vasodilator in neonatal pharmacotherapy, particularly in the Indian context where iNO availability is limited. Its oral bioavailability, low cost, and wide availability make it uniquely suited to managing PPHN across all tiers of Indian healthcare. Careful dose titration guided by blood pressure monitoring, serial oxygenation assessment, and echocardiographic evaluation ensures safe and effective use. As Indian NICUs continue to advance, sildenafil will remain a cornerstone of PPHN management alongside expanding access to inhaled nitric oxide.